Cooperation of Musashi-2, Numb, MDM2, and P53 in drug resistance and malignant biology of pancreatic cancer

The circadian clock gene Bmal1 acts as a potential anti-oncogene in pancreatic cancer by activating the p53 tumor suppressor pathway

(2016) Weiliang Jiang et al.   CANCER LETTERS

Musashi-2 promotes migration and invasion in bladder cancer via activation of the JAK2/STAT3 pathway

(2016) Chenlu Yang et al.   LABORATORY INVESTIGATION

Musashi-2 (MSI2) supports TGF-β signaling and inhibits claudins to promote non-small cell lung cancer (NSCLC) metastasis

(2016) Alexander E. Kudinov et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

WP1130 increases doxorubicin sensitivity in hepatocellular carcinoma cells through usp9x-dependent p53 degradation

(2015) Hao Liu et al.   CANCER LETTERS

Musashi-2 Silencing Exerts Potent Activity against Acute Myeloid Leukemia and Enhances Chemosensitivity to Daunorubicin

(2015) Yixiang Han et al.   PLoS One

Transformation of the intestinal epithelium by the MSI2 RNA-binding protein

(2015) Shan Wang et al.   Nature Communications

p53 controls colorectal cancer cell invasion by inhibiting the NF-κB-mediated activation of Fascin

(2015) Xinbing Sui et al.   Oncotarget

Interleukin 6 downregulates p53 expression and activity by stimulating ribosome biogenesis: a new pathway connecting inflammation to cancer

(2014) E Brighenti et al.   ONCOGENE

Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer

(2014) Taofeek K. Owonikoko et al.   Cancer Medicine

Cisplatin-induced non-apoptotic death of pancreatic cancer cells requires mitochondrial cyclophilin-D-p53 signaling

(2013) Bo Chen et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Cooperation among Numb, MDM2 and p53 in the development and progression of pancreatic cancer

(2013) Weiwei Sheng et al.   CELL AND TISSUE RESEARCH

Musashi2 predicts poor prognosis and invasion in hepatocellular carcinoma by driving epithelial-mesenchymal transition

(2013) Lu He et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Overexpression of Calreticulin Contributes to the Development and Progression of Pancreatic Cancer

(2013) Weiwei Sheng et al.   JOURNAL OF CELLULAR PHYSIOLOGY

MSI2 expression is decreased in grade II of gastric carcinoma

(2013) Modjtaba Emadi-Baygi et al.   PATHOLOGY RESEARCH AND PRACTICE

The SOX2-Interactome in Brain Cancer Cells Identifies the Requirement of MSI2 and USP9X for the Growth of Brain Tumor Cells

(2013) Jesse L. Cox et al.   PLoS One

Musashi 2 in hematopoiesis

(2012) Luisa de Andrés-Aguayo et al.   CURRENT OPINION IN HEMATOLOGY

Musashi2 Is Required for the Self-Renewal and Pluripotency of Embryonic Stem Cells

(2012) Erin L. Wuebben et al.   PLoS One

MSI2 protein expression predicts unfavorable outcome in acute myeloid leukemia

(2011) R. J. Byers et al.   BLOOD

Musashi1: A stem cell marker no longer in search of a function

(2011) Robert I. Glazer et al.   CELL CYCLE

An RNAi Screen Identifies Msi2 and Prox1 as Having Opposite Roles in the Regulation of Hematopoietic Stem Cell Activity

(2010) Kristin J. Hope et al.   Cell Stem Cell

c-Abl Phosphorylation of Mdm2 Facilitates Mdm2-Mdmx Complex Formation

(2010) David L. Waning et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Regulation of myeloid leukaemia by the cell-fate determinant Musashi

(2010) Takahiro Ito et al.   NATURE

Mutant p53 mediates survival of breast cancer cells

(2009) L Y Lim et al.   BRITISH JOURNAL OF CANCER

Mutant p53 Gain-of-Function in Cancer

(2009) M. Oren et al.   Cold Spring Harbor Perspectives in Biology

NUMB controls p53 tumour suppressor activity

(2008) Ivan N. Colaluca et al.   NATURE